Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Urelumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Urelumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Urelumab. |
| Estrone | Estrone may increase the thrombogenic activities of Urelumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Urelumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Urelumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Urelumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Urelumab. |
| Estriol | Estriol may increase the thrombogenic activities of Urelumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Urelumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Urelumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Urelumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Urelumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Urelumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Urelumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Urelumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Urelumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Urelumab. |
| Equol | Equol may increase the thrombogenic activities of Urelumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Urelumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Urelumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Urelumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Urelumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Urelumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Urelumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Urelumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Urelumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Urelumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Urelumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Urelumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Urelumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Urelumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Urelumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Urelumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Urelumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Urelumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Urelumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Urelumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Urelumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Urelumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Urelumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Urelumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Urelumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Urelumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Urelumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Urelumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Urelumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Urelumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Urelumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Urelumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Urelumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Urelumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Urelumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Urelumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Urelumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Urelumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Urelumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Urelumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Urelumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Urelumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Urelumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Urelumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Urelumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Urelumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Urelumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Urelumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Urelumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Urelumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Urelumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Urelumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Urelumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Urelumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Urelumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Urelumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Urelumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Urelumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Urelumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Urelumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Urelumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Urelumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Urelumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Urelumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Urelumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Urelumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Urelumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Urelumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Urelumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Urelumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Urelumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Urelumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Urelumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Urelumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Urelumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Urelumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Urelumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Urelumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Urelumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Urelumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Urelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Urelumab. |